Showing results (461-470 of 482) with videos related to
Sort By:
Pageof 49
Journal of Clinical Medicine|February 25, 2022
Temporal Trends of Major Bleeding and Its Prediction by the Academic Research Consortium-High Bleeding Risk Criteria in Acute Myocardial InfarctionSungwook Byun, Eun Ho Choo, Gyu-Chul Oh, et al.Journal of Natural Products|October 12, 2016
Stachybotrysin, an Osteoclast Differentiation Inhibitor from the Marine-Derived Fungus Stachybotrys sp. KCB13F013Jong Won Kim, Sung-Kyun Ko, Hye-Min Kim, et al.Investigative and Clinical Urology|September 5, 2023
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapySeung-Hwan Jeong, Sang Eun Yeon, Su Youn Kim, et al.Coronary Artery Disease|December 3, 2015
Prognostic importance of mitral regurgitation complicated by acute myocardial infarction during a 5-year follow-up period in the drug-eluting stent eraTae-Hoon Kim, Kwan Yong Lee, Young Choi, et al.Pharmacogenetics and Genomics|August 8, 2013
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary interventionMahn-Won Park, Sung Ho Her, Ho-Sook Kim, et al.Journal of Human Hypertension|September 14, 2021
Visit-to-visit blood pressure variability and mortality and cardiovascular outcomes after acute myocardial infarctionEun Ho Choo, Ji-Su Mok, Woo Baek Chung, et al.Journal of Clinical Medicine|November 13, 2021
Gender Differences in the Impact of New-Onset Atrial Fibrillation on Long-Term Risk of Ischemic Stroke after Acute Myocardial InfarctionJeong-Eun Yi, Suk-Min Seo, Sungmin Lim, et al.The World Journal of Men'S Health|January 2, 2024
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate CancerDong Jin Park, Tae Gyun Kwon, Jae Young Park, et al.Clinical Therapeutics|August 1, 2021
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III StudyJong Shin Woo, Soon Jun Hong, Dong Hoon Cha, et al.Nature|May 6, 2026
Non-invasive profiling of the tumour microenvironment with spatial ecotypesWubing Zhang, Erin L Brown, Abul Usmani, et al.Pageof 49